Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea

Diabetes Research and Clinical Practice

Volumn 54, Issue 1, 2001, Pages 9-15

  Hirose, Takahisa ^a   Miyashita, Yoshihiro ^b   Takagi, Miki ^b   Sumitani, Satoru ^b   Kouhara, Haruhiko ^b   Kasayama, Soji ^b  

^a Nishinomiya Municipal Central Hospital   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glucosidase inhibitor; Homeostasis model assessment (HOMA); Sulfonylurea; Voglibose

Indexed keywords

ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; HEMOGLOBIN A1C; SULFONYLUREA; VOGLIBOSE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 0034856531     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(01)00282-0     Document Type: Article

References (21)

1. α-Glocosidase inhibitors in diabetes: efficacy in NIDDM subjects
2. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus
3. Pharmacological modification of digestion and absorption
4. α-Glocosidase inhibitors as agents in the treatment of diabetes
5. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone
6. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations
7. Hyperinsulinemia as an independent risk factor for ischemic heart disease
8. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients
9. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial
10. Effect of an α-glucosidase inhibitor (voglibose), in combination with sulfonylureas, on glycaemic control in type 2 diabetes patients
11. Synthesis and α-D-glucosidase activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents
12. Correct homeostasis model assessment (HOMA) evaluation uses the computer program
13. Regulation of hepatic glucose metabolism in humans
14. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
15. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients
16. Effects of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients
17. Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improves insulin sensitivity in diet-treated type II diabetic patients?
18. on behalf of the UKPDS Study Group, A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
19. Chronic treatment of African American type 2 diabetic patients with α-glucosidase inhibition
20. An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM
21. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate